Mattig, Isabel
Steudel, Tilman
Klingel, Karin
Barzen, Gina
Frumkin, David
Spethmann, Sebastian
Romero Dorta, Elena
Stangl, Karl
Heidecker, Bettina
Landmesser, Ulf
Knebel, Fabian
Canaan-Kühl, Sima
Hahn, Katrin
Brand, Anna
Funding for this research was provided by:
Alnylam Pharmaceuticals
Charité - Universitätsmedizin Berlin
Article History
Received: 11 August 2023
Accepted: 24 January 2024
First Online: 30 January 2024
Competing interests
: Isabel Mattig is participant in the BIH Charité Clinician Scientist Program funded by the Charité – Universitätsmedizin Berlin and the Berlin Institute of Health at Charité (BIH). She received research grants from Pfizer Pharmaceuticals, lecture fee and financial reimbursement for advisory board activities from Sanofi outside the submitted work. Katrin Hahn achieved financial reimbursement for consulting, advisory board activities and travel support by Akcea Therapeuticals Inc., Alnylam Pharmaceuticals Inc., Swedish Orphan Biovitrum, and Pfizer Pharmaceuticals, research funding by Alnylam Pharmaceuticals Inc., and Pfizer Pharmaceuticals as well as research funding by the foundation Charité (BIH clinical fellow). AB received lecture fee from Pfizer Pharmaceuticals. All other author have no competing interest. All author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.